The Low Carb Diabetic

Promoting a low carb high fat lifestyle for the safe control of diabetes. Eat whole fresh food, more drugs are not the answer.


Welcome to the Low Carb Diabetic forum,have you signed up yet? if not then sign up and join us in the low carb community today!

    The BMJ logo Search Research Education News & Views Campaigns Archive For authors Jobs Hosted CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population

    yoly
    yoly
    Member

    Status :
    Online
    Offline

    Posts : 645
    Join date : 2014-08-14

     The BMJ logo Search      Research     Education     News & Views     Campaigns      Archive     For authors     Jobs     Hosted  CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population  Empty The BMJ logo Search Research Education News & Views Campaigns Archive For authors Jobs Hosted CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population

    Post by yoly on Tue May 14 2019, 12:53

    https://www.bmj.com/content/365/bmj.l1204

    CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population

    Accepted 11 March 2019

    Abstract

    Objective To investigate the incidence of new onset type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors (dutasteride or finasteride) for long term treatment of benign prostatic hyperplasia.

    Design Population based cohort study.

    Setting UK Clinical Practice Research Datalink (CPRD; 2003-14) and Taiwanese National Health Insurance Research Database (NHIRD; 2002-12).

    Participants Men in the CPRD who received dutasteride (n=8231), finasteride (n=30 774), or tamsulosin (n=16 270) were evaluated. Propensity score matching (2:1; dutasteride to finasteride or tamsulosin) produced cohorts of 2090, 3445, and 4018, respectively. In the NHIRD, initial numbers were 1251 (dutasteride), 4194 (finasteride), and 86 263 (tamsulosin), reducing to 1251, 2445, and 2502, respectively, after propensity score matching.

    Main outcomes measure Incident type 2 diabetes using a Cox proportional hazard model.

    Results In the CPRD, 2081 new onset type 2 diabetes events (368 dutasteride, 1207 finasteride, and 506 tamsulosin) were recorded during a mean follow-up time of 5.2 years (SD 3.1 years). The event rate per 10 000 person years was 76.2 (95% confidence interval 68.4 to 84.0) for dutasteride, 76.6 (72.3 to 80.9) for finasteride, and 60.3 (55.1 to 65.5) for tamsulosin. There was a modest increased risk of type 2 diabetes for dutasteride (adjusted hazard ratio 1.32, 95% confidence interval 1.08 to 1.61) and finasteride (1.26, 1.10 to 1.45) compared with tamsulosin. Results for the NHIRD were consistent with the findings for the CPRD (adjusted hazard ratio 1.34, 95% confidence interval 1.17 to 1.54 for dutasteride, and 1.49, 1.38 to 1.61 for finasteride compared with tamsulosin). Propensity score matched analyses showed similar results.

    Conclusions The risk of developing new onset type 2 diabetes appears to be higher in men with benign prostatic hyperplasia exposed to 5α-reductase inhibitors than in men receiving tamsulosin, but did not differ between men receiving dutasteride and those receiving finasteride. Additional monitoring might be required for men starting these drugs, particularly in those with other risk factors for type 2 diabetes.
    yoly
    yoly
    Member

    Status :
    Online
    Offline

    Posts : 645
    Join date : 2014-08-14

     The BMJ logo Search      Research     Education     News & Views     Campaigns      Archive     For authors     Jobs     Hosted  CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population  Empty Re: The BMJ logo Search Research Education News & Views Campaigns Archive For authors Jobs Hosted CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population

    Post by yoly on Tue May 14 2019, 12:55

    5α-Reductase Type 1 Modulates Insulin Sensitivity in Men

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207930/

    Abstract
    Context:

    5α-Reductase (5αR) types 1 and 2 catalyze the A-ring reduction of steroids, including androgens and glucocorticoids. 5α-R inhibitors lower dihydrotestosterone in benign prostatic hyperplasia; finasteride inhibits 5αR2, and dutasteride inhibits both 5αR2 and 5αR1. In rodents, loss of 5αR1 promotes fatty liver.
    Objective:

    Our objective was to test the hypothesis that inhibition of 5αR1 causes metabolic dysfunction in humans.
    Design, Setting, and Participants:

    This double-blind randomized controlled parallel group study at a clinical research facility included 46 men (20–85 years) studied before and after intervention.
    Intervention:

    Oral dutasteride (0.5 mg daily; n = 16), finasteride (5 mg daily; n = 16), or control (tamsulosin; 0.4 mg daily; n = 14) was administered for 3 months.
    Main Outcome Measure:

    Glucose disposal was measured during a stepwise hyperinsulinemic-euglycemic clamp. Data are mean (SEM).

    Results:

    Dutasteride and finasteride had similar effects on steroid profiles, with reduced urinary androgen and glucocorticoid metabolites and reduced circulating DHT but no change in plasma or salivary cortisol. Dutasteride, but not finasteride, reduced stimulation of glucose disposal by high-dose insulin (dutasteride by −5.7 [3.2] μmol/kg fat-free mass/min, versus finasteride +7.2 [3.0], and tamsulosin +7.0 [2.0]). Dutasteride also reduced suppression of nonesterified fatty acids by insulin and increased body fat (by 1.6% [0.6%]). Glucose production and glycerol turnover were unchanged. Consistent with metabolic effects of dutasteride being mediated in peripheral tissues, mRNA for 5αR1 but not 5αR2 was detected in human adipose tissue.

    Conclusion:

    Dual inhibition of 5αRs, but not inhibition of 5αR2 alone, modulates insulin sensitivity in human peripheral tissues rather than liver. This may have important implications for patients prescribed dutasteride for prostatic disease.

      Current date/time is Mon Oct 14 2019, 14:06